OKYO Pharma shares are trading higher after the company announced a new agreement with Tufts Medical Center to conduct a 40-patient open-label clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain.
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has announced a new agreement with Tufts Medical Center to conduct a 40-patient open-label clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain. This has led to a rise in OKYO Pharma's share prices.
July 28, 2023 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OKYO Pharma's shares are trading higher after the announcement of a new clinical trial agreement with Tufts Medical Center.
The announcement of a new clinical trial agreement is a positive development for OKYO Pharma. This indicates progress in their research and development efforts, which is likely to be viewed favorably by investors, leading to an increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100